We are live on
!
Find out more
PC
Paulson & Co Portfolio holdings
AUM
$3.11B
1-Year Est. Return
94.93%
This Fund
S&P 500
This Quarter
Est. Return
-4.85%
1 Year Est. Return
+94.93%
3 Year Est. Return
+233.32%
5 Year Est. Return
+258.51%
10 Year Est. Return
+934.97%
AUM
$1.12B
AUM Growth
+$93.3M
(+9.1%)
Cap. Flow
+$180M
Cap. Flow
% of AUM
16.08%
Top 10 Holdings %
Top 10 Hldgs %
92.48%
Holding
21
New
–
Increased
2
Reduced
–
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$172M |
| 2 |
Madrigal Pharmaceuticals
MDGL
|
+$28.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Newmont
NEM
|
+$19.3M |
| 2 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$984K |
| 3 |
DSEY
Diversey Holdings, Ltd. Ordinary Shares
DSEY
|
+$420K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 47.75% |
| 2 | Materials | 31.68% |
| 3 | Financials | 15.53% |
| 4 | Technology | 3.36% |
| 5 | Real Estate | 0.74% |
Similar funds
TCG
CCI
DIG
EAM
LFG
DCM
HCM
BI
Paulson & Co's Q3 2023 Portfolio in Review
As of Q3 2023, Paulson & Co held 21 positions worth $1.12B, up 9.1% from $1.02B the previous quarter. Its ten largest holdings account for 92% of the portfolio.
Paulson & Co deployed $180M of net new capital in Q3 2023, adding to 2 existing holdings.
By sector, the portfolio is most concentrated in Healthcare at 48% of assets, up from 34% a quarter earlier, followed by Materials and Financials.
On the sell side, the most notable exit was Newmont, an estimated $19.3M sold.
- Paulson & Co added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2023, an estimated $172M increase.
- Paulson & Co fully exited Newmont in Q3 2023, selling an estimated $19.3M.
- Paulson & Co's ten largest holdings make up 92% of its $1.12B portfolio in Q3 2023.
- Paulson & Co opened 0 new positions and closed 3 in Q3 2023.
- Paulson & Co's portfolio value rose 9.1% quarter-over-quarter to $1.12B.
Based on Paulson & Co's 13F filing for Q3 2023, filed 14 Nov 2023.